{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:24:36Z","timestamp":1794266676556,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA131965"],"award-info":[{"award-number":["1R01CA131965"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ygyno.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T02:08:58Z","timestamp":1584583738000},"page":"514-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience"],"prefix":"10.1016","volume":"157","author":[{"given":"Shannon K.","family":"Rush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle L.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn P.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy J.","family":"Agnew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Kilgore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.","family":"Norquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.02.006_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ygyno.2020.02.006_bb0010","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ygyno.2020.02.006_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2020.02.006_bb0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.ygyno.2020.02.006_bb0025","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality","volume":"305","author":"Buys","year":"2011","journal-title":"Jama"},{"key":"10.1016\/j.ygyno.2020.02.006_bb0030","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ygyno.2020.02.006_bb0035","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.ygyno.2020.02.006_bb0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.ygyno.2020.02.006_bb0045","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.955","article-title":"Mutations in BRIP1 confer high risk of ovarian cancer","volume":"43","author":"Rafnar","year":"2011","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.ygyno.2020.02.006_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"26","key":"10.1016\/j.ygyno.2020.02.006_bb0055","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2020.02.006_bb0060","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"And MSH6 genes in lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA J Am Med Assoc."},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.006_bb0065","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ijc.23508","article-title":"The risk of extra-colonic, extra-endometrial cancer in the lynch syndrome","volume":"123","author":"Watson","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"29","key":"10.1016\/j.ygyno.2020.02.006_bb0070","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","article-title":"Cancer risks for PMS2-associated lynch syndrome","volume":"36","author":"ten Broeke","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2020.02.006_bb0075","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ygyno.2020.02.006_bb0080","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.02.006_bb0085","unstructured":"Genetic\/familial high-risk assessment: breast and ovarian. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf. Published 2018. Accessed May 16, 2018."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.006_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: a new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ygyno.2020.02.006_bb0095","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.ajog.2006.03.006","article-title":"Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy","volume":"194","author":"Lamb","year":"2006","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.02.006_bb0100","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IGC.0b013e31821bc7e3","article-title":"Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers","volume":"21","author":"Powell","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2020.02.006_bb0105","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/sj.bjc.6601692","article-title":"Clinical outcome of prophylactic oophorectomy in BRCA1\/BRCA2 mutation carriers and events during follow-up","volume":"90","author":"Olivier","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.006_bb0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","article-title":"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","volume":"100","author":"Finch","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.006_bb0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/1940-6207.CAPR-10-0266","article-title":"Microscopic and early-stage ovarian cancers in brca1\/2 mutation carriers: building a model for early BRCA-associated tumorigenesis","volume":"4","author":"Yates","year":"2011","journal-title":"Cancer Prev. Res."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.006_bb0120","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2012.07.021","article-title":"Support of the \u201cfallopian tube hypothesis\u201d in a prospective series of risk-reducing salpingo-oophorectomy specimens","volume":"49","author":"Reitsma","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.02.006_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.02.006_bb0130","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jmig.2017.04.017","article-title":"Assessing the risk of occult cancer and 30-day morbidity in women undergoing risk-reducing surgery: a prospective experience","volume":"24","author":"Bogani","year":"2017","journal-title":"J. Minim. Invasive Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.006_bb0135","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11845-017-1717-6","article-title":"Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes","volume":"187","author":"Thompson","year":"2018","journal-title":"Ir. J. Med. Sci."},{"issue":"29","key":"10.1016\/j.ygyno.2020.02.006_bb0140","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group trial GOG-0199","volume":"32","author":"Sherman","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.006_bb0145","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2013.01.029","article-title":"Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy","volume":"129","author":"Powell","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.02.006_bb0150","first-page":"1","article-title":"An alternate diagnostic algorithm for the diagnosis of intraepithelial fallopian tube lesions","author":"Perrone","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.006_bb0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00000478-200202000-00003","article-title":"Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or \u22122 mutations: implications for gross examination, cytology, and clinical follow-up","volume":"26","author":"Agoff","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.006_bb0165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1006\/gyno.2002.6638","article-title":"Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy","volume":"85","author":"Colgan","year":"2002","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.006_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-2011-5","article-title":"The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review","volume":"16","author":"Blok","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.02.006_bb0175","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bbcan.2014.06.003","article-title":"PALB2: the hub of a network of tumor suppressors involved in DNA damage responses","volume":"1846","author":"Park","year":"2014","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2020.02.006_bb0180","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","article-title":"Contribution to familial breast cancer of inherited mutations in the BRCA2-interacting protein PALB2","volume":"71","author":"Casadei","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2020.02.006_bb0185","doi-asserted-by":"crossref","unstructured":"Kanchi KL, Johnson KJ, Lu C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat. Commun. 2014:1\u201314. doi:https:\/\/doi.org\/10.1038\/ncomms4156.","DOI":"10.1038\/ncomms4156"},{"key":"10.1016\/j.ygyno.2020.02.006_bb0190","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.006_bb0195","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-015-1597-y","article-title":"Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study","volume":"15","author":"Harmsen","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.02.006_bb0200","first-page":"8","article-title":"Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1\/2 mutations","author":"Nebgen","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2020.02.006_bb0205","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820301013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820301013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:52:34Z","timestamp":1758772354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820301013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0090825820301013"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.02.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}